Cel Sci Corporation (CVM)

[drkazmd65]

If they win ~$40 MM, then they get to pocket ~81.25% of $30 MM. Or about $24.3 MM.

If they are not actively trying to recruit new patients for the Phase III, then the cash burn shouldn't be too sig through late 2018 or sometime in 2019 when the Phase III patient read-outs are done. Running the trial was a very expensive piece of their operating budgets.

As the bulk of the patients that Erogmed added didn't come until 2015-2016, and we have to wait 3 years post-treatment for the survivors to be counted as survivors - if the trial is done and sufficient data is collected in Mid 2019, I'm guessing that approval would come in early 2020.... maybe.

But a successful trial has the added benefit of very likely significantly raising share prices even before approval, and possibly attracting lucrative licensing or partnerships for CVM.

Lots of 'ifs' in the meantime, but at least with a significant win in the Arbitration - the pressure on us shareholders lightens significantly short-term.